Skip to main content

Gorman Kevin Charles's Form 4 filing

Neurocrine Biosciences IncNBIX · filed Feb 14, 2025

Accession no.
0000914475-25-000073
Filed
Feb 14, 2025
Trade date
Feb 13, 2025
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $681.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gorman Kevin CharlesCIK 0001201096Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 13, 2025Common StockMOption exerciseAcquired+5,376$0.00$0524,450Direct
Feb 13, 2025Common StockSSaleDisposed−2,832$116.69F2−$330,466.08521,618Direct
Feb 13, 2025Common StockMOption exerciseAcquired+5,603$0.00$0527,221Direct
Feb 13, 2025Common StockSSaleDisposed−3,012$116.68F4−$351,440.16524,209Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 13, 2025Common StockMOption exerciseDisposed−5,376$0.00$010,754Direct
Feb 13, 2025Common StockMOption exerciseDisposed−5,603$0.00$016,812Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.92 to $117.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F4

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)